Berubicin: Anthracyclines inhibit the topoisomerase II enzyme to disrupt DNA and RNA synthesis by intercalating between base pairs of the DNA/RNA strand, thus preventing the replication of rapidly growing cancer cells.

Berubicin is a novel, synthetic, second-generation anthracycline-based topoisomerase II inhibitor engineered to circumvent the the BBB and overcome MDR.  Berubicin has been administered to humans in 4 clinical trials to date.  

Anthracyclines inhibit the topoisomerase II enzyme to disrupt DNA and RNA synthesis by intercalating between base pairs of the DNA/RNA strand.

Summer of Primary Analysis

• Showed clinically relevant outcomes comparable to Lomustine across multiple endpoints¹
• Safety profile continues to be favorable, including the absence of anthracycline related cardiotoxicity
• Analysis of outcomes are ongoing, including advanced imaging review, PK, and clinical endpoints

Ongoing Analysis of Outcomes

1. Did not demonstrate a statistically significant difference in overall survival, the primary endpoint

• Evaluated in multiple Phase 1 and Phase 2 studies
• Fast Track Designation
• Orphan Drug Designation with 7 years market exclusivity in the U.S.
• On-going GBM trial.